, Asbestos International Agency for Research on Cancer edn, 1977.
, , p.493
A review of human carcinogens--part C: metals, 494 arsenic, dusts, and fibres, Lancet Oncol, vol.10, pp.453-454, 2009. ,
Occupational exposure to asbestos and ovarian cancer: a meta-analysis, Environ Health Perspect, vol.496, 2011. ,
, Asbestos International Agency for Research on Cancer edn, 1977.
, , p.493
A review of human carcinogens--part C: metals, 494 arsenic, dusts, and fibres, Lancet Oncol, vol.10, pp.453-454, 2009. ,
Occupational exposure to asbestos and ovarian cancer: a meta-analysis, Environ Health Perspect, vol.496, pp.1211-1217, 2011. ,
Asbestos-induced lung diseases: an update, Transl Res, vol.153, pp.143-152, 2009. ,
The health impact of nonoccupational exposure to asbestos: what do 500 we know?, Eur J Cancer Prev, vol.18, pp.489-503, 2009. ,
Molecular and genetic changes in 502 asbestos-related lung cancer, Cancer Lett, vol.265, pp.1-15, 2008. ,
, , p.504, 2012.
, Changes in Mesothelioma With an Impact on Prognosis and Treatment, Arch Pathol Lab Med, vol.136, p.277
, , p.507
TP53 and KRAS mutation load and types in lung cancers in relation 508 to tobacco smoke: distinct patterns in never, former, and current smokers, Cancer Res, vol.65, pp.5076-5083, 2005. ,
, , p.510, 2000.
, Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons, J Natl Cancer Inst, vol.511, issue.92, pp.803-811
Malignant mesothelioma, Lancet, vol.366, p.11, 2005. ,
, , p.514
, , p.515
, , pp.16-20, 2010.
, inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos, Cancer, vol.517, pp.23-30
, , p.519
Guidelines for mineral fibre analyses in biological samples: report 520 of the ERS Working Group, Eur Respir J, vol.11, p.13, 1998. ,
Retention of asbestos bodies in the lungs of welders, Am J Ind Med, vol.522, p.14, 1994. ,
, , p.524
, , p.525, 2011.
, Risk of lung cancer and occupational history: results of a French population-based case-control study, the 526 ICARE study, J Occup Environ Med, vol.53, pp.1068-1077
, , p.528
In vitro effects of recombinant human interferon gamma on human mesothelioma 529 cell lines, Int J Cancer, vol.55, pp.515-520, 1993. ,
, , p.531
Pleural mesothelioma and exposure to asbestos: evaluation from 532 work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 533 patients, Occup Environ Med, vol.51, pp.244-249, 1994. ,
, , p.535
, , p.536
Guidelines of the European Respiratory Society and 537 the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur, vol.538, 2010. ,
, , vol.35, pp.479-495
) k-ras 540 mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without 541 asbestosis, Cancer Res, vol.59, pp.4570-4573, 1999. ,
, , p.543
Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations, Am 544 J Respir Cell Mol Biol, vol.20, pp.667-674, 1999. ,
, , p.546
Mutations in the p53 gene in lung cancer are associated with cigarette smoking and 41, 1995. ,
polymorphisms: cancer implications, Nat Rev, p.599, 2009. ,
, Cancer, vol.9, pp.95-107
Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) 602 prognosis, Cancer Invest, vol.601, pp.168-172, 2008. ,
TP53 polymorphisms and lung cancer risk: a 604 systematic review and meta-analysis, Mutagenesis, vol.18, pp.377-385, 2003. ,
, , p.606
Polymorphisms in human dopamine D2 receptor gene affect gene, pp.20552-20557, 2007. ,
, , p.610
Identification of common genetic variation that 611 modulates alternative splicing, PLoS Genet, vol.3, p.46, 2007. ,
Genetic variants associated with breast-613 cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence, Lancet, vol.614, 2011. ,
, Oncol, vol.12, p.47
, , p.616
Association between DNA damage response and 617 repair genes and risk of invasive serous ovarian cancer, PLoS One, vol.5, p.10061, 2010. ,